Abstract
Purpose: To investigate the prognostic relevance of temporal muscle thickness (TMT) as a surrogate parameter of skeletal muscle status in patients with newly diagnosed glioblastoma. Experimental Design: We assessed TMT in cranial MRI of 755 patients enrolled in the CENTRIC EORTC 26071-22072 study (n= 508) and CORE study (n = 247). We used predefined sex-specific TMTcut-off values to categorize "patients at risk of sarcopenia" and "patients with normal muscle status" at baseline. Furthermore, we categorized patients according to the extent of TMT loss over time. Associations with progression-free survival (PFS) and overall survival (OS) were evaluated using the Cox model adjusted for other exploratory variables. Results: Patients at risk of sarcopenia (CENTRIC; n = 158/ 508, 31.1%; CORE; n = 87/247, 35.2%) at baseline had significantly higher risk of progression and death than patients with normal muscle status in both study cohorts [CENTRIC: PFS = HR 0.16; 95% confidence interval (CI), 0.12-0.21; P < 0.001; OS = HR 0.341; 95% CI, 0.27-0.44; P < 0.001; CORE: PFS = HR 0.29; 95% CI, 0.21-0.39; P < 0.001; OS = HR, 0.365; 95% CI, 0.27-0.49; P < 0.001]. Similar results were obtained in multivariate Cox models adjusted for other important prognostic parameters. The extent of TMT loss over time showed a significant inverse correlation with median OS times in patients at risk for sarcopenia (CENTRIC: P < 0.001; CORE: P = 0.005), but not in patients with normal baseline muscle mass (CENTRIC: P = 0.538; CORE: P = 0.28). Conclusions: TMT identifies ambulatory patients with newly diagnosed glioblastoma at risk for progressive sarcopenia and adverse outcomes. Early intervention may prevent skeletal muscle loss and improve patient outcome.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 129-136 |
| Number of pages | 8 |
| Journal | Clinical Cancer Research |
| Volume | 28 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2022 |
Funding
M. Weller reports grants and personal fees from Apogenix, MSD, and Merck (EMD); grants from Quercis; and personal fees from Adastra, BMS, Medac, Nerviano, Novartis, Orbus, Philogen and yMabs outside the submitted work. L.B. Nabors reports other support from Univ Penn and personal fees from Karyo-pharm outside the submitted work. D.A. Reardon reports personal fees from Abbvie Pharmaceuticals, Advantagene, Agios, Amgen, AnHeart Therapeutics, Bayer, Boston Biomedical, Boehringer Ingelheim, Deciphera, Del Mar Pharma, DNAtrix, Ellipses Pharma, Genenta, Genentech/Roche, Imvax, Kintara, Kiyatec, Medicenna Biopharma, Merck, Merck KGaA, Monteris, Novocure, Oncorus, Oxigene, Regeneron, Stemline, Sumitono Dainippon Pharma, Pyramid, Taiho Oncology, Inc., Tragara, and Y-Mabs Therapeutics; grants from Acerta Pharmaceuticals, Epitopoietic Research Corporation, Enterome, Incyte, Insightec, and Omniox; and grants and personal fees from Agenus, Bristol-Myers Squibb, Celldex, EMD Serono, Inovio, and Novartis outside the submitted work. J. Tonn reports personal fees from CarThera; grants from Novocure; and non-financial support from Munich Surgical Imaging and BrainLab outside the submitted work. R. Stupp reports personal fees and non-financial support from CarThera and personal fees from Celularity, CranioVation/Alpheus, Hemispherian, Insightec, GT Medical Technologies, Northwest Biotherapeutics, TriAct, AstraZeneca,
ASJC Scopus subject areas
- General Medicine
